Secondary Logo

Journal Logo

Perioperative medicine

PREPARE

the prevalence of perioperative anaemia and need for patient blood management in elective orthopaedic surgery

A multicentre, observational study

Lasocki, Sigismond; Krauspe, Rüdiger; von Heymann, Christian; Mezzacasa, Anna; Chainey, Suki; Spahn, Donat R.

Author Information
European Journal of Anaesthesiology (EJA): March 2015 - Volume 32 - Issue 3 - p 160-167
doi: 10.1097/EJA.0000000000000202
  • Free

Abstract

Introduction

Preoperative anaemia is a common condition among patients undergoing elective surgery.1–3 Depending on the cohort under investigation, the reported prevalences reach up to 75%4 and in orthopaedic surgery range from 7 to 35%.5,6 Preoperative anaemia is associated with an increased risk of postoperative morbidity1,7–10 and mortality1,3,11–13 as well as prolonged hospital stay.3,8,13 In addition, preoperatively anaemic patients are more likely to receive perioperative red blood cell (RBC) transfusions than nonanaemic patients.4,9,11,14 Hip and knee arthroplasties are among the surgical procedures most commonly associated with RBC transfusions.2

Analyses of large numbers of surgical patients showed a dose-dependent association between RBC transfusion and adverse outcomes such as increased mortality, morbidity and sepsis.15–17 A Cochrane review of 19 randomised controlled studies comparing restrictive vs. liberal transfusion strategies in 6264 patients showed that the restricted use of RBC transfusions had no adverse influence on functional recovery or length of hospital stay.18 Restrictive transfusion strategies were associated with a statistically significant reduction in hospital mortality and a numerical reduction in 30-day mortality that was close to being statistically significant. Interestingly, one trial in critically ill patients showed a significant association between restricted transfusion and lower mortality rates among subgroups with less severe conditions (APACHE II score ≤20) and lower age (<55 years).19 Overall, the available data suggest that rather than being a first-line anaemia treatment, RBC transfusions should be the last resort.20,21 An approach that is intended to reduce RBC transfusion is called patient blood management (PBM) and is based on three pillars: correction of preoperative anaemia, reduction of perioperative blood loss and managing iron status.2,21,22

The implementation of PBM has resulted in better postsurgical outcome and considerable financial savings.23–26 Recently, an expert panel, and the European Society of Anaesthesiology, have both underscored the need for preoperative evaluation and treatment of anaemia.23,27 The need to implement PBM is also being increasingly recognised by clinicians; yet little is known about its penetration into European centres.28 This observational study assessed the pre and postoperative prevalence and management of anaemia in patients undergoing elective orthopaedic surgery in Europe.

Materials and methods

Study design and patients

This study was designed as an observational, multicentre study across six European countries. According to local legislation, the study protocol, any protocol amendments and the patient consent form were submitted to institutional review boards and ethics committees for review and approval. The study was conducted in compliance with the International Conference on Harmonisation of Good Clinical Practice and all applicable local and national guidelines and regulations. From November 2010 to March 2011, trained medical staff collected anonymised data on patient and treatment characteristics, haematological and laboratory test results, as well as treatment outcomes and complications from patient records via electronic case report forms. All collected data were subject to a plausibility and quality check. Entries that did not pass the plausibility and quality check were verified by phone interviews.

Up to 100 patients per centre, who consecutively completed elective orthopaedic hip, knee or spine surgery between 1 January 2010 and 1 July 2010, were included in reverse chronological order of the date of completing the surgical procedure. Eligible patients were 18 to 80 years of age, had a preoperative assessment within 1 day to 6 weeks prior to surgery, at least one pre and one postoperative haemoglobin (Hb) level (maximum 4 weeks after surgery) available and provided written informed consent if required by local regulations. Patients would have been excluded from participation if surgery was an emergency (no time for preoperative anaemia management), if the procedure was outside the scope of this study, if they were pregnant at the time of surgery and if there was a history of major surgical intervention within 4 weeks prior to the elective orthopaedic procedure.

Participation did not require any additional visits or assessments. The administration of RBC transfusion followed institutional policies. Centres with an institutional, preoperative erythropoietin or iron treatment protocol to treat or prevent preoperative anaemia were considered as a PBM centre. Use of antifibrinolytics was not recorded.

Objectives

Primary endpoint was the prevalence of preoperative anaemia according to the WHO criteria [Hb <13 g dl−1 (male), Hb <12 g dl−1 (female)] in patients undergoing elective orthopaedic surgery. Secondary endpoints were patient outcomes such as prevalence of postoperative anaemia, transfused RBC volume and time to the first RBC transfusion (exclusive of the use of cell saver blood), length of stay (LOS) as well as perioperative anaemia treatment regimens used. In addition, the incidence of postoperative complications such as deep vein thrombosis, pulmonary embolism, bleeding, myocardial infarction/ischaemia, arrhythmia, stroke, hypotension, urinary tract infection, renal failure, wound infection, sepsis and laboratory abnormalities (other than electrolyte disturbances) were recorded using site-specific definitions. Adverse drug reactions and serious adverse events were not recorded.

Blood loss was calculated from pre and postoperative haematocrit (HCT) values, intraoperatively administered transfusion volume (VTx in litres) and estimated blood volume according to the following formula:29

BV = a + b*preop-weight (kg) 1000–1; (for males a = 1530 and b = 41, for females a = 864 and b = 47.9).

Statistical methods

The proposed sample size of 1100 to 1500 patients was based on assumptions30 about minimum differences found between preoperatively anaemic and nonanaemic patients, with a power of more than 90% and two-sided alpha of 5%. On the basis of the results of a systematic review,2 minimum detectable differences for patients transfused, the number of RBC units given and LOS was set to 9.9%, 0.7 RBC units and 1.0 days, respectively.

Descriptive statistical analysis summarised continuous data by mean (standard deviation, SD), median with 25 and 75% quartiles (Q1, Q3) as appropriate or minimum and maximum values. Categorical data were summarised by the number and percentage of individuals in each category. Analysis of variance (ANOVA) or analysis of covariance (ANCOVA) was used for comparison of continuous data and logistic regression was used for categorical data (SAS version 9.3; SAS Inc., Cary, North Carolina, USA). Missing data were treated as missing.

Multivariate models were conducted using age, sex, American Society of Anesthesiologists (ASA) Physical Status class, anaemic status, transfusion type, surgical procedure, enrolment in a PBM centre and the interaction between PBM centre and transfusion type as covariates. Only covariates remaining statistically significant at a level of 5% (i.e. age, transfusion type and enrolment in a PBM centre) were kept in the final model. Normality of the distribution of the data was explored using the Shapiro–Wilk test and by mean of distribution plots. Sensitivity analyses were conducted by excluding extreme values and applying log-transformation in order to confirm the results of the main analysis.

Results

Patient characteristics

Data from all 1534 screened patient records who underwent elective orthopaedic surgery of the hip (765, 49.9%), knee (570, 37.2%) or spine (199, 13.0%) in 17 centres in six countries (Austria, France, Germany, The Netherlands, Spain and UK) were collected and analysed (Table 1). Mean age of patients was 64.0 years and 938 (61.3%) were female. Baseline (preoperative) SBP and DBP were comparable for preoperatively anaemic and nonanaemic patients. Seven (41%) of the 17 centres that enrolled 635 (41.4%) patients were considered as PBM centres.

Table 1
Table 1:
Patient baseline characteristics

Anaemia prevalence

Prior to surgery, 217 (14.1%) patients were anaemic (Fig. 1) and this proportion increased to 1315 (85.8%) postoperatively. The prevalence of preoperative anaemia was comparable in patients for hip and knee surgery (12.9 and 13.2%, respectively) but higher in patients undergoing surgery of the spine (21.6%; P = 0.001 vs. hip and knee combined). No patient had a preoperative Hb level less than 8 g dl−1. Postoperatively, the prevalence of Hb less than 8 g dl−1 was 13.9% among preoperatively anaemic and 2.1% among nonanaemic preoperative patients (P < 0.001) (overall 3.7%). The median time between the last preoperative Hb assessment and surgery was 1 day (1 to 15) for preoperatively anaemic and 7 days (1 to 25) for nonanaemic preoperative patients (P < 0.001). Postoperatively, 83.8% of nonanaemic preoperative patients became anaemic and 97.7% of preoperatively anaemic patients remained anaemic (P < 0.001). In PBM centres, the prevalence of preoperative anaemia was lower than in non-PBM centres (8.0 vs. 18.5%; P < 0.001), whereas the prevalence of postoperative anaemia was similar (84.3 vs. 86.8%; P = 0.249). The prevalence of postoperative Hb levels less than 8 g dl−1 was lower in PBM than in non-PBM centres (overall 1.4 vs. 5.3%, P < 0.001; preoperatively anaemic patients 17.0 vs. 3.9%, P < 0.019).

Fig. 1
Fig. 1:
Prevalence of pre and postoperative anaemia and incidence of perioperative anaemia treatment by site of surgery (seeTable 2 for split of perioperative anaemia treatment into type of treatment and phase of administration).

Mean fall in Hb was larger in nonanaemic preoperative patients [−3.0 (1.3) g dl−1] than in preoperatively anaemic patients [−1.9 (1.5) g dl−1; P < 0.001; adjusted for procedure and sex]. Overall, mean Hb levels decreased from 13.7 (1.5) g dl−1 preoperatively to 10.8 (1.6) g dl−1 postoperatively (P < 0.001) without significant differences between the different procedures. Mean Hb change was −2.9 (1.4) g dl−1 overall and similar in PBM and non-PBM centres [−2.9 (1.4) and − 2.8 (1.4) g dl−1, respectively]. Calculated blood loss was 1.68 l (range 0.07 to 7.83 l) in nonanaemic preoperative patients and 1.93 l (0.07 to 12.27 l) in those anaemic preoperatively (P = 0.016).

Postoperative outcomes

Preoperatively anaemic patients experienced a higher rate of postoperative complications (36.9 vs. 22.2%; P = 0.009) and a longer hospital stay (11.7 ± 9.6 vs. 8.8 ± 5.9 days; P < 0.001) than those with no preoperative anaemia, which is in accord with a higher rate of ASA scores 3 to 4 among preoperatively anaemic vs. nonanaemic patients (35.1 and 18.4%, respectively). Multivariate analyses after adjustment for sex, age, ASA and preoperative anaemia status showed that LOS is independently associated with receipt of a RBC transfusion and enrolment in a non-PBM centre (Table 2). Also, patients who had received a RBC transfusion and were adjusted for ASA and surgical procedure had a higher risk of postoperative complications than patients without RBC transfusions (Table 2). Overall, excluding electrolyte disturbances, hypotension, vomiting, bleeding and urinary retention, the most common postoperative complications were laboratory abnormalities (Table 3).

Table 2
Table 2:
Association of length of stay and postoperative complications with red blood cell transfusion and enrolment in a nonpatient blood management centre
Table 3
Table 3:
Postoperative complications in the overall population and stratified by preoperative anaemia status and type of centre (patient blood management vs. nonpatient blood management centre)

Assessment of iron status and inflammation

Iron status was only assessed in a small percentage (<10%) of patients. Serum ferritin was assessed in 93 patients (6%) overall, with a higher rate in PBM vs. non-PBM centres [n = 70 (11.0%) vs. n = 23 (2.6%); P < 0.001]. Preoperative mean serum ferritin levels were similar between PBM and non-PBM centres [100 (108) vs. 124 (110) ng ml−1; P = 0.36] and between anaemic [n = 12 (5.5%)] and nonanaemic [n = 81 (6.2%)] patients [104 (90) vs. 106 (111) ng ml−1; P = 0.946]. Among nonanaemic preoperative patients with available ferritin levels who became anaemic after surgery, 47 (61.8%) had preoperative serum ferritin levels less than 100 ng ml-1, indicating iron deficiency.1 Preoperative transferrin saturation (TSAT) was almost exclusively assessed in PBM centres [n = 70 (11.0%) vs. n = 1 (0.1%); P < 0.001]. TSAT was lower in preoperatively anaemic [20.9 (11.3)%; n = 6] than in nonanaemic patients [30.0 (9.5)%; n = 65; P = 0.031].

C-reactive protein (CRP) was assessed in 364 (27.6%) of nonanaemic preoperative patients and 62 (28.6%) of anaemic patients. Median CRP levels were 0.26 (0.10 to 0.51) and 0.49 (0.20 to 1.77) g l−1, respectively (maximum levels 6.78 and 24.8 g l−1).

Anaemia management

Perioperative anaemia was treated in 131 (60.4%) of preoperatively anaemic and 395 (30.0%) nonanaemic preoperative patients [P < 0.0001; overall 526 (34.3%), Fig. 1, Table 4]. Anaemia treatment predominantly consisted of RBC transfusion [267 (50.8%) allogeneic, 161 (30.6%) autologous (% of treated patients)] followed by iron supplementation [127 (24.1%) oral, 74 (14.1%) intravenous iron]. The use of erythropoiesis-stimulating agents (ESAs) was uncommon (overall 1.4% of all patients). Allogeneic RBC transfusion and oral iron were more frequently used for preoperative anaemia than in patients not anaemic preoperatively (P < 0.001). The use of autologous RBC transfusion was similar in preoperatively anaemic and nonanaemic patients (P = 0.416).

Table 4
Table 4:
Perioperative anaemia management by preoperative anaemia status and type of centre (patient blood management vs. nonpatient blood management centre). More than one treatment per patient was possiblea

Blood from cell salvage procedures was used in 152 (9.9%) patients overall, with comparable rates among those with allogeneic or without RBC transfusion (6.0 and 9.0%, respectively; P = 0.132). Among the 161 patients receiving autologous RBC transfusion, 35 (21.7%) also received cell salvage blood (P < 0.0001 vs. patients with nonautologous RBC transfusion). The majority of transfused patients received at least 2 RBC units and the mean number of units per patient was similar, although statistically different between preoperatively anaemic and nonanaemic patients [2.4 (1.5) vs. 2.2 (1.4) units, P < 0.001]. Median (Q1, Q3) time to first intraoperative RBC transfusion (excluding cell saver blood) was 130 min (88, 158) in anaemic compared with 179 min (135, 256) in nonanaemic patients (P < 0.001; adjusted by procedure).

The percentage of patients who had received a RBC transfusion varied considerably across participating centres. In non-PBM centres, more patients received allogeneic RBC transfusions than in PBM centres (21.2 vs. 11.7%; P < 0.001, Table 4), whereas the use of autologous RBC transfusion was comparable (10.8 vs. 10.1%; P = 0.487). Overall, patients with knee surgery had the lowest rate of transfusion during surgery (2.1%) compared with 4.7% and 10.6% among patients undergoing hip or spine procedures, respectively.

Discussion

This observational study has shown that a relatively low proportion of patients (14.1%) present with preoperative anaemia but a very much higher proportion (85.7%) become anaemic after elective major orthopaedic surgery. Overall, patients experienced a mean decrease in Hb levels of 2.9 g dl−1, which probably translated into the high rate of postoperative anaemia. Notably, a considerable proportion of patients became severely anaemic (Hb <8 g dl−1) after surgery with a higher prevalence in non-PBM than in PBM centres, and particularly among those who were already anaemic (17.0%). Together with the finding that PBM measures are underused, the high rate of postoperative anaemia underscores the need for effective PBM that goes beyond treating preoperative anaemia to include reducing intraoperative blood loss and immediate postoperative anaemia, and managing iron status.

The observed prevalence of preoperative anaemia in our study compares with the findings in reported studies in orthopaedic surgery (7 to 35%).5,6 The prevalence of postoperative anaemia is also in the range reported for hip fracture surgery (74 to 93%)2 and hip or knee arthroplasty (95%).31 Given the drop in Hb when comparing pre and postoperative values, a blood loss calculation was performed on the basis of measured haematocrit values and administered RBC transfusion. The high calculated blood loss values are in line with the high rate of postoperative anaemia despite a rather low prevalence of preoperative anaemia in this patient group.

Statistical analysis of data from the entire cohort suggests an association between preoperative anaemia, a higher rate of postoperative complications and also a longer hospital stay. This association probably reflects the more severe underlying conditions that are indicated by higher ASA scores among the preoperatively anaemic patients. However, the correlation between LOS, receipt of a RBC transfusion and admission to a non-PBM centre remained after adjustment for ASA, preoperative anaemia status and also sex and age. The immediate pretransfusion Hb levels have not been recorded and so we cannot verify whether differences in transfusion rates correlate with different Hb levels, as transfusion triggers vary across centres. Nevertheless, these findings are in line with previous publications7–10 and corroborate the results of a recent study by Musallam et al.,1 which analysed database entries from 227 425 patients undergoing noncardiac surgery. In this study, perioperative transfusion in itself was found to be associated with increased mortality and morbidity. Furthermore, the prevalence of preoperative anaemia was 30.4%, with anaemia being independently and significantly associated with increased 30-day morbidity. Data from our audit complement the findings by Musallam et al.1 by providing detailed insights into the defined subgroup of elective orthopaedic surgery patients, additionally including data on pre, intraoperative and postoperative anaemia management and assessment of iron status.

Despite recommendations that were published long before the patients in this study underwent surgery,32 the percentage assessed for iron status in the preoperative period was very low (<10%) and consistent with iron being underused as a treatment option. Even in PBM centres, only a minority of patients were tested for their ferritin levels or TSAT, suggesting the need for an evaluation of how PBM is actually implemented in centres claiming to be a PBM centre. Iron status assessment is not expensive and could be systematically performed in this high-risk population.

Lower TSAT in preoperatively anaemic patients may indicate the presence of iron deficiency in this subgroup. Notably, 57 patients (61.3% of tested patients) had baseline serum ferritin levels less than 100 ng ml−1 and most of them (47 patients) became anaemic postoperatively; eight had already been anaemic preoperatively. However, we cannot evaluate the prevalence of iron deficiency in the entire study population. Interestingly, the average time between last Hb measurement and surgery was more than 1 week and was longer among nonanaemic patients. This suggests that there is time to institute preoperative anaemia management.

Notably, even among preoperatively anaemic patients, only a minority of patients received anaemia treatment such as iron or ESA. Moreover, most iron-treated patients, even those with preoperative anaemia, received oral iron despite the known limitations of oral vs. intravenous (i.v.) iron.33,34

Since this study, it has been shown that pre and intraoperative treatment of anaemia reduces postoperative morbidity, transfusion requirement and length of hospital stay.23,35,36 However, considering the high estimates of postoperative anaemia in this and other studies2,31 and the fact that iron deficiency is a main cause of anaemia,37 appropriate iron status assessment should become part of pre and postoperative routine anaemia evaluation and management.

The high reliance on RBC transfusion is a concern. Despite continuous improvement in the production and management of RBC concentrate, there will always be a risk of transmitting new or re-emerging blood borne pathogens,38,39 and perioperative transfusions per se are associated with increased morbidity and mortality even when only a single RBC unit is administered.15,17,40 Our statistical analysis identified RBC transfusion as an independent risk factor of postoperative complications and prolonged hospitalisation (Table 2). Despite adjustment for known confounding factors, we cannot rule out that there may be additional unidentified reasons for this.

Interestingly, around 40% of RBC transfusions were autologous RBC concentrates. Furthermore, cell salvage blood was used more frequently in patients who had received autologous transfusions than in those who had received allogeneic or no transfusion. This may reflect institutional approaches towards blood conservation, as reducing blood loss and use of autologous blood salvage make up part of the second and third pillars of PBM;22,30 yet, there were not enough data to analyse for statistical differences between centres.

Our findings indicate that PBM measures such as iron status assessment, i.v. iron treatment and erythropoietic stimulation are still underused in orthopaedic surgery in Europe. As most patients in our study became anaemic after surgery, correction of preoperative anaemia is only one important aspect of PBM. Providing patients with sufficient iron reserve to cope with the blood loss during surgery (1 ml blood corresponds approximately to 0.5 mg iron, for a 80 kg man) and addressing the impaired utilisation of iron due to chronic disease or surgery-associated activation of proinflammatory cytokines is just as important.41,42 The benefits of postoperative i.v. iron treatment have recently been shown;43 however, there appears to be a need to increase awareness about the role of iron in the development and treatment of anaemia, in addition to differences between oral and i.v. iron administration that can render oral iron therapy inadequate or ineffective.44,45

Due to the observational nature of the study, interpretation of our results is limited by the absence of a reference arm and the lack of control over the frequency and duration of treatment or the frequency of performed laboratory tests. Also, additional information about the use of antifibrinolytics might have allowed a better understanding of the high blood loss, as these agents may have influenced bleeding and transfusion requirement. On the positive side, studies such as this one reflect realities of clinical practice and show the implementation (or ignorance) of treatment recommendations and clinical evidence. Observational studies can provide the basis for new hypotheses or identify patient groups that benefit most from a certain treatment. The observed higher blood loss in preoperatively anaemic than in nonanaemic patients may have a purely mathematical explanation. As blood loss is equal to the RBC loss divided by the mean haematocrit during blood loss, the lower mean haematocrit during blood loss in preoperatively anaemic vs. nonanaemic patients (0.318 vs. 0.364; P < 0.001), resulted in a higher calculated blood loss. Mean RBC loss was similar in preoperatively anaemic and nonanaemic patients, respectively.

In conclusion, the results of this observational study show that most patients who underwent elective orthopaedic surgery had normal preoperative Hb levels but became anaemic after the procedure. Patients were rarely tested for their iron status and anaemia treatment was dominated by RBC transfusion despite evidence of their potential negative effects, whereas the pharmacological treatment of anaemia was underused and recent recommendations were ignored.

Acknowledgements relating to this article

Assistance with the study: Medical writing support was provided by SFL Regulatory Affairs & Scientific Communication.

Financial support and sponsorship: This work was supported by Vifor Pharma Ltd. who sponsored the study, supported development of the study design, provided organisational and statistical support and funded medical writing support.

Conflicts of interests: S Lasocki has received speaker honoraria from Vifor Pharma and Janssen-Cilag, and served as a consultant for Vifor Pharma. R Krauspe served as consultant for Vifor Pharma. For the purpose of this study, C von Heymann has received research funding from Vifor Pharma, Janssen-Cilag and The German Red Cross, and honoraria for lectures and consultancy work from Vifor Pharma and Janssen-Cilag. A Mezzacasa and S Chainey are employees of Vifor Pharma. DR Spahn's academic department is receiving grant support from Vifor Pharma Deutschland GmbH, Munich, Germany, Vifor Pharma Österreich GmbH, Vienna, Austria, Vifor (International) AG, St. Gallen, Switzerland.

Presentation: Data have been presented in a poster form at Euroanaesthesia 2012, 9 to 12 June, Paris, France.

References

1. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in noncardiac surgery: a retrospective cohort study. Lancet 2011; 378:1396–1407.
2. Spahn DR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology 2010; 113:482–495.
3. Baron DM, Hochrieser H, Posch M, et al. Preoperative anaemia is associated with poor clinical outcome in noncardiac surgery patients. Br J Anaesth 2014; 113:416–423.
4. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007; 47:1468–1480.
5. Enko D, Wallner F, von-Goedecke A, et al. The impact of an algorithm-guided management of preoperative anemia in perioperative hemoglobin level and transfusion of major orthopedic surgery patients. Anemia 2013; 2013:641876.
6. Theusinger OM, Leyvraz PF, Schanz U, et al. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: a prospective study. Anesthesiology 2007; 107:923–927.
7. Dunkelgrun M, Hoeks SE, Welten GM, et al. Anemia as an independent predictor of perioperative and long-term cardiovascular outcome in patients scheduled for elective vascular surgery. Am J Cardiol 2008; 101:1196–1200.
8. Gruson KI, Aharonoff GB, Egol KA, et al. The relationship between admission hemoglobin level and outcome after hip fracture. J Orthop Trauma 2002; 16:39–44.
9. Myers E, O’Grady P, Dolan AM. The influence of preclinical anaemia on outcome following total hip replacement. Arch Orthop Trauma Surg 2004; 124:699–701.
10. Sakr Y, Lobo S, Knuepfer S, et al. Anemia and blood transfusion in a surgical intensive care unit. Crit Care 2010; 14:R92.
11. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 2009; 110:574–581.
12. Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055–1060.
13. Wu WC, Schifftner TL, Henderson WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 2007; 297:2481–2488.
14. Zheng F, Cammisa FP Jr, Sandhu HS, et al. Factors predicting hospital stay, operative time, blood loss, and transfusion in patients undergoing revision posterior lumbar spine decompression, fusion, and segmental instrumentation. Spine (Phila Pa 1976) 2002; 27:818–824.
15. Bernard AC, Davenport DL, Chang PK, et al. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg 2009; 208:931–937.
16. Ferraris VA, Davenport DL, Saha SP, et al. Surgical outcomes and transfusion of minimal amounts of blood in the operating room. Arch Surg 2012; 147:49–55.
17. Kulier A, Levin J, Moser R, et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007; 116:471–479.
18. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2012; 4:CD002042.
19. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409–417.
20. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist 2011; 16 (Suppl 3):12–18.
21. Spahn DR, Goodnough LT. Alternatives to blood transfusion. Lancet 2013; 381:1855–1865.
22. Shander A, Javidroozi M, Perelman S, et al. From bloodless surgery to patient blood management. Mt Sinai J Med 2012; 79:56–65.
23. Kotze A, Carter LA, Scally AJ. Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle. Br J Anaesth 2012; 108:943–952.
24. LaPar DJ, Crosby IK, Ailawadi G, et al. Blood product conservation is associated with improved outcomes and reduced costs after cardiac surgery. J Thorac Cardiovasc Surg 2013; 145:796–803.
25. Moskowitz DM, McCullough JN, Shander A, et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? Ann Thorac Surg 2010; 90:451–458.
26. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50:753–765.
27. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30:270–382.
28. Williamson LM, Devine DV. Challenges in the management of the blood supply. Lancet 2013; 381:1866–1875.
29. Hakim RM, Siami GA. Plasmapheresis. In: Daugirdas JT, Ing TS, editors. Handbook of dialysis. Boston/New York/Toronto/London: Little, Brown and Company; 1994. 18–241.
30. Spahn DR, Moch H, Hofmann A, Isbister JP. Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology 2008; 109:951–953.
31. Rosencher N, Kerkkamp HE, Macheras G, et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003; 43:459–469.
32. Beris P, Munoz M, Garcia-Erce JA, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100:599–604.
33. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008; 121:943–948.
34. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69:739–756.
35. Na HS, Shin SY, Hwang JY, et al. Effects of intravenous iron combined with low-dose recombinant human erythropoietin on transfusion requirements in iron-deficient patients undergoing bilateral total knee replacement arthroplasty. Transfusion 2011; 51:118–124.
36. Yoo YC, Shim JK, Kim JC, et al. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011; 115:929–937.
37. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001; 131:568S–579S.
38. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006; 355:1303–1305.
39. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 (Suppl 2):1S–29S.
40. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008; 36:2667–2674.
41. Ganz T, Nemeth E. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med 2012; 2:a011668.
42. Munoz M, Garcia-Erce JA, Cuenca J, et al. On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery. Blood Transfus 2012; 10:8–22.
43. Bisbe E, Molto L, Arroyo R, et al. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth 2014; 113:402–409.
44. Lachance K, Savoie M, Bernard M, et al. Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty. Ann Pharmacother 2011; 45:764–770.
45. Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg 2005; 87:213–217.
© 2015 European Society of Anaesthesiology